Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026
I'm LongbridgeAI, I can summarize articles.
Entrada Therapeutics updated its corporate presentation, highlighting favorable safety and significant functional gains in ENTR-601-44 Cohort 1 for DMD. Cohort 2 data is expected by year-end 2026, with ongoing dosing. The company anticipates multiple catalysts in 2026 and has a cash runway into Q3 2027.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments